Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin vs Plasmalyte for Sepsis-Induced Hypotension in Cirrhosis
NCT02721238Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Dec 2016
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of albumin (human) in sepsis and hypotension (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Reversal of hypotension in both groups at 3 hours. Started Dec 2016; status: completed.
02
Drugs
albumin (human)
03
Conditions
sepsishypotension
Beyond the preview
Go deeper on NCT02721238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02721238.